Published in Ophthalmology on May 22, 2013
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond) (2015) 1.22
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol (2013) 1.17
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond) (2015) 1.10
Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol (2015) 1.05
Efficacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience. Int Ophthalmol (2015) 1.03
A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond) (2015) 0.92
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmol (2015) 0.89
Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up. Ophthalmol Eye Dis (2016) 0.85
Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond) (2014) 0.84
Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials. Drug Des Devel Ther (2015) 0.83
Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study. J Ocul Pharmacol Ther (2014) 0.81
A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye (Lond) (2015) 0.81
Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmol Ther (2016) 0.80
Evolving strategies in the management of diabetic retinopathy. Middle East Afr J Ophthalmol (2013) 0.80
Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. J Ophthalmol (2016) 0.77
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations. Retina (2015) 0.77
Updates on the Clinical Trials in Diabetic Macular Edema. Middle East Afr J Ophthalmol (2016) 0.77
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol (2016) 0.77
Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy. Retina (2015) 0.76
Simultaneous Therapy with Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema. Med Hypothesis Discov Innov Ophthalmol (2016) 0.75
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes (2015) 0.75
Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Prefer Adherence (2017) 0.75
Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol (2015) 0.75
Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. Clin Ophthalmol (2016) 0.75
Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema. Korean J Ophthalmol (2017) 0.75
Report of 12-months efficacy and safety of intravitreal fluocinalone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond) (2017) 0.75
The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis. PLoS One (2016) 0.75
Diabetic Retinopathy and Diabetic Macular Edema. Dev Ophthalmol (2015) 0.75
Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des Devel Ther (2014) 0.75
Corticosteroid Treatment in Diabetic Macular Edema. Turk J Ophthalmol (2017) 0.75
Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema. Open Ophthalmol J (2017) 0.75
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
A high-resolution map of active promoters in the human genome. Nature (2005) 24.35
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods (2006) 8.52
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res (2006) 6.54
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol (2006) 4.55
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol (2003) 4.34
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology (2013) 3.92
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature (2007) 3.32
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04
Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem (2005) 3.03
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev (2006) 2.78
Evidence-based National Vaccine Policy. Indian J Med Res (2010) 2.75
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30
Quality of sleep and health-related quality of life in haemodialysis patients. Nephrol Dial Transplant (2003) 2.20
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Cosmetic facial fillers and severe vision loss. JAMA Ophthalmol (2014) 2.20
Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol (2004) 2.18
High-power, computer-controlled, light-emitting diode-based light sources for fluorescence imaging and image-guided surgery. Mol Imaging (2009) 2.15
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol (2006) 2.10
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 2.07
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol (2006) 2.04
Spontaneous corneal hydrops and perforation in keratoconus and pellucid marginal degeneration. Cornea (2003) 2.00
Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol (2009) 1.99
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. Retina (2016) 1.92
Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol (2008) 1.89
Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A (2009) 1.84
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med (2002) 1.81
Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes. Am J Ophthalmol (2008) 1.81
p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal (2011) 1.80
In vivo identification of regulators of cell invasion across basement membranes. Sci Signal (2010) 1.77
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol (2010) 1.75
Imaging pulsatile retinal blood flow in human eye. J Biomed Opt (2008) 1.73
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol (2009) 1.63
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A (2012) 1.59
Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. Trials (2014) 1.56
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
Association of educational, occupational and socioeconomic status with cardiovascular risk factors in Asian Indians: a cross-sectional study. PLoS One (2012) 1.53
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46
LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) (2013) 1.46
Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment. Retina (2012) 1.46
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology (2009) 1.45
Evaluating teaching methods of cataract surgery: validation of an evaluation tool for assessing surgical technique of capsulorhexis. J Cataract Refract Surg (2012) 1.42
Gestational diabetes mellitus--Indian guidelines. J Indian Med Assoc (2009) 1.40
Toward an optimal position for inferior vena cava filters: computational modeling of the impact of renal vein inflow with Celect and TrapEase filters. J Vasc Interv Radiol (2010) 1.39
Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem (2009) 1.37
Extracellular polymeric substances (EPS) of microbial aggregates in biological wastewater treatment systems: a review. Biotechnol Adv (2010) 1.35
Gestational diabetes mellitus--guidelines. J Assoc Physicians India (2006) 1.35
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis (2007) 1.28
A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res (2011) 1.27
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol (2005) 1.26
Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol (2007) 1.26
Mitochondrial DNA haplogroups associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.26
Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (2006) 1.25
Prevalence of gestational diabetes mellitus (GDM) and its outcomes in Jammu region. J Assoc Physicians India (2011) 1.25
Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina (2012) 1.24
Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci U S A (2012) 1.23
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology (2005) 1.22
Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001. Indian J Med Res (2006) 1.21
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology (2012) 1.19
Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina (2014) 1.18
Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging. J Biol Chem (2008) 1.18
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood (2009) 1.17
Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci (2006) 1.17